Author:
Epling Brian P.,Rocco Joseph M.,Boswell Kristin L.,Laidlaw Elizabeth,Galindo Frances,Kellogg Anela,Das Sanchita,Roder Allison,Ghedin Elodie,Kreitman Allie,Dewar Robin L.,Kelly Sophie E. M.,Kalish Heather,Rehman Tauseef,Highbarger Jeroen,Rupert Adam,Kocher Gregory,Holbrook Michael R.,Lisco Andrea,Manion Maura,Koup Richard A.,Sereti Irini
Abstract
AbstractClinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe disease or impaired antibody and T-cell responses in people with rebound symptoms.
Publisher
Cold Spring Harbor Laboratory
Reference13 articles.
1. Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) Center for Drug Evaluation and Research (CDER) Review. In: Center for Drug Evaluation and Research (CDER); 2021.
2. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
3. Charness M , Gupta K , Stack G , et al. Rapid Relapse of Symptomatic Omicron SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. medRxiv Preprint. 2022.
4. Gupta K , Strymish J , Stack G , Charness M. Rapid Relapse of Symptomatic SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. medRxiv Preprint. 2022.
5. Bennett RS , Postnikova EN , Liang J , et al. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples. Viruses. 2021;13(5).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献